Abstract
BackgroundIdentifying non-invasive and reliable blood-derived biomarkers for early detection of acute cellular rejection in heart transplant recipients is of great importance in clinical practice. MicroRNAs are small molecules found to be stable in serum and their expression patterns reflect both physiological and underlying pathological conditions in human.MethodsWe compared a group of heart transplant recipients with histologically-verified acute cellular rejection (ACR, n = 26) with a control group of heart transplant recipients without allograft rejection (NR, n = 37) by assessing the levels of a select set of microRNAs in serum specimens.ResultsThe levels of seven microRNAs, miR-142-3p, miR-101-3p, miR-424-5p, miR-27a-3p, miR-144-3p, miR-339-3p and miR-326 were significantly higher in ACR group compared to the control group and could discriminate between patients with and without allograft rejection. MiR-142-3p and miR-101-3p had the best diagnostic test performance among the microRNAs tested. Serum levels of miR-142-3p and miR-101-3p were independent of calcineurin inhibitor levels, as measured by tacrolimus and cyclosporin; kidney function, as measured by creatinine level, and general inflammation state, as measured by CRP level.ConclusionThis study demonstrated two microRNAs, miR-142-3p and miR-101-3p, that could be relevant as non-invasive diagnostic tools for identifying heart transplant patients with acute cellular rejection.
Highlights
The main goal of post heart transplantation care is to prevent allograft rejection while minimizing the dose of immunosuppressive treatment
The levels of seven microRNAs, miR-142-3p, miR-101-3p, miR-424-5p, miR-27a-3p, miR144-3p, miR-339-3p and miR-326 were significantly higher in acute cellular rejections (ACR) group compared to the control group and could discriminate between patients with and without allograft rejection
This study demonstrated two microRNAs, miR-142-3p and miR-101-3p, that could be relevant as non-invasive diagnostic tools for identifying heart transplant patients with acute cellular rejection
Summary
The main goal of post heart transplantation care is to prevent allograft rejection while minimizing the dose of immunosuppressive treatment. Identifying non-invasive and reliable biomarkers for early detection of acute cellular rejection is of great importance and has become a major challenge in solid organ transplantation[6,7]. In a previous pilot study, using samples from heart transplant patients treated at Skane University Hospital (Lund, Sweden), we demonstrated proof-of-principle that the profile of serum microRNAs is altered during ACR and that miR-142-3p can discriminate significantly between histologically-verified normal and diseased states[11]. MiR-142-3p and miR-101-3p had the best diagnostic performance among the seven microRNAs tested, making them the potential candidates as non-invasive biomarkers for ACR surveillance post hearttransplantation. Identifying non-invasive and reliable blood-derived biomarkers for early detection of acute cellular rejection in heart transplant recipients is of great importance in clinical practice. MicroRNAs are small molecules found to be stable in serum and their expression patterns reflect both physiological and underlying pathological conditions in human
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
